IE 11 is not supported. For an optimal experience visit our site on another browser.

Video Interview: Marc Beer, CEO, Aegerion Pharmaceuticals, Inc. (AEGR)

/ Source: GlobeNewswire

NEW YORK, Oct. 29, 2010 (GLOBE NEWSWIRE) -- Veteran business journalist Joya Dass joins Marc Beer, CEO, Aegerion Pharmaceuticals, Inc. (AEGR), to discuss the company's industry, strategy and positioning.

Click here to view video:

Biography – Marc Beer

Marc Beer was appointed Chief Executive Officer in August 2010 and brings over 20 years of experience in biotechnology, pharmaceuticals and diagnostics to Aegerion.

In April 2000, Marc became the founding CEO of Viacell (VIAC), a biotechnology company specializing in the collection and preservation of umbilical cord blood stem cells, and over a period of 7 years led the company from its inception to a rapidly growing and robust commercial organization. Under Marc's leadership, the company grew to more than 300 employees, went public in 2005 and was ultimately acquired in 2007 by PerkinElmer (PKI).

Prior to founding Viacell, Marc held various positions within Genzyme (GENZ), most recently as Vice President of Global Marketing where he was responsible for the commercial launch of several products addressing orphan disease populations on a global scale. Prior to Genzyme, he held a variety of sales and marketing roles in the pharmaceutical and diagnostic divisions of Abbott Laboratories (ABT).

He also previously served on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Body and was a former member of the Mass Life Science Board of the Commonwealth of Massachusetts.

Marc currently holds the following board seats: Chairman, TxCell, Nice, France; Chairman, Good Start Genetics, Cambridge, MA; Board Member, Seaside Therapeutics, Cambridge, MA. Mr. Beer holds a B.S. from Miami University.

About Aegerion Pharmaceuticals, Inc. (AEGR):

Aegerion Pharmaceuticals (Nasdaq:AEGR) is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics for rare genetic disorders. The Company's first commercial product in late-stage clinical development, lomitapide, is a small molecule, oral therapy to treat severe lipid disorders for an orphan patient population. 

For more information on the opportunity to have your CEO discuss your company, please call NASDAQ CEO Signature Series, 978/461-3141.

The NASDAQ CEO Signature Series logo is available at